Top 10 Owners of Vaxart Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| SSgA Funds Management, Inc. | 10.42% | 13,072,021 |
| BlackRock Fund Advisors | 6.14% | 7,709,060 |
| The Vanguard Group, Inc. | 4.52% | 5,668,354 |
| D. E. Shaw & Co. LP | 1.70% | 2,126,924 |
Similarly Who is VXRT stock? (VXRT) Stock Price, News, Quote & History – Yahoo Finance.
…
Performance Outlook.
| Previous Close | 4.8800 |
|---|---|
| Day’s Range | 4.6550 – 4.8700 |
| 52 Week Range | 3.9100 – 11.1100 |
| Volume | 1,515,390 |
| Avg. Volume | 2,417,308 |
Who is Andrei Floroiu? Founder of Fly for MS, Andrei Floroiu is Director, Chief Executive & Financial Officer of Vaxart, Inc.
Additionally, Does vaxart have Phase 2?
Vaxart began its Phase II COVID-19 oral vaccine trials in the U.S. in October 2021 . Data is expected in the first half of 2022.
Why is vaxart dropping?
The biotech’s stock has been sliding hard over the past month and half for two related reasons: Vaxart’s oral COVID-19 vaccine pill may not be on the market until the pandemic is starting to fade from the daily news cycle.
How many shares of VXRT are there? Share Statistics
| Avg Vol (3 month) 3 | 2.86M |
|---|---|
| Shares Outstanding 5 | 125.5M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 124.61M |
| % Held by Insiders 1 | 0.71% |
Why is VXRT up today? What happened. Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for its oral coronavirus vaccine. As of 2:20 p.m. EDT, Vaxart’s stock price was up more than 12%.
Should you buy VXRT stock? Out of 4 analysts, 3 (75%) are recommending VXRT as a Strong Buy, 0 (0%) are recommending VXRT as a Buy, 1 (25%) are recommending VXRT as a Hold, 0 (0%) are recommending VXRT as a Sell, and 0 (0%) are recommending VXRT as a Strong Sell.
Will VXRT stock go up tomorrow?
If this Munafa value is near or nearing 100, then this stock might show an upward movement.
…
Munafa value: 40 as on 08 Fri Apr 2022.
| Downside target | 4.5 |
|---|---|
| Upside target | 4.79 |
| Upside target | 4.87 |
| Upside target | 4.88 |
| Upside target | 5.04 |
Is vaxart a good buy? The verdict. While Vaxart’s oral vaccine could be a game-changer if approved, it is nowhere near reaching that milestone. A lot can still go wrong for the company, and since it does not currently have any products on the market and is consistently unprofitable, that makes the company’s shares very risky.
What does vaxart Inc do?
Vaxart, Inc. operates as a biotechnology company. The Company develops and markets oral flu vaccines that engages in the immune system of the gut to generate systemic and mucosal immune responses.
Who owns OCGN? Top 10 Owners of Ocugen Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.21% | 11,209,731 |
| The Vanguard Group, Inc. | 4.69% | 10,096,039 |
| Geode Capital Management LLC | 1.52% | 3,274,335 |
| JPMorgan Asset Management (UK) Lt… | 1.49% | 3,197,615 |
Is vaxart a public company?
Vaxart has a collaborative development program for oral delivery of a vaccine against universal flu using proprietary antigens from Janssen Pharmaceutica (Janssen Vaccines and Prevention B.V.).
…
Vaxart.
| Vaxart’s HQ located in South San Francisco | |
|---|---|
| Type | Public |
| Traded as | Nasdaq: VXRT |
| Industry | Biotechnology |
| Founded | 2004 |
Is vaxart a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank.
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
How do I buy VXRT stock? Find the stock by name or ticker symbol – VXRT – and research it before deciding if it’s a good investment for you. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price. Check in on your investment.
What is vaxart future? According to the 4 industry analysts covering Vaxart, the consensus is that breakeven is near. They expect the company to post a final loss in 2022, before turning a profit of US$6.4m in 2023. The company is therefore projected to breakeven around 2 years from today.
What is the forecast for vaxart?
The 4 analysts offering 12-month price forecasts for Vaxart Inc have a median target of 11.50, with a high estimate of 18.00 and a low estimate of 7.00. The median estimate represents a +146.25% increase from the last price of 4.67.
Should I hold my vaxart stock? Vaxart finds support from accumulated volume at $4.62 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock has average movements during the day and with good trading volume, the risk is considered to be medium.
Is VXRT a buy or sell?
Out of 4 analysts, 3 (75%) are recommending VXRT as a Strong Buy, 0 (0%) are recommending VXRT as a Buy, 1 (25%) are recommending VXRT as a Hold, 0 (0%) are recommending VXRT as a Sell, and 0 (0%) are recommending VXRT as a Strong Sell. What is VXRT’s earnings growth forecast for 2022-2024?
Why is vaxart stock up? Is It Too Late to Buy Vaxart Stock? Shares of biotech Vaxart (NASDAQ: VXRT) soared back in 2020 following enthusiasm that the company would eventually become a leader in the COVID-19 vaccine market.
Where is vaxart located?
Vaxart
| Vaxart’s HQ located in South San Francisco | |
|---|---|
| Founder | Sean Tucker |
| Headquarters | South San Francisco, California |
| Key people | Andrei « Andy » Floroiu (CEO) |
| Products | Oral vaccines |
What type of vaccine is vaxart? Vaxart is primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform.
How old is vaxart Inc? Vaxart Inc (NASDAQ:VXRT)
It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.
Is Ocugen a buy Zacks?
How good is it? See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank.
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
Is Vanguard invested in OCGN?
2022-02-10 – Vanguard Group Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 10,605,494 shares of Ocugen Inc (US:OCGN). This represents 5.32 percent ownership of the company.
Who is holding OCGN? Largest shareholders include State Street Corp, BlackRock Inc., Vanguard Group Inc, XBI – SPDR(R) S&P(R) Biotech ETF, VTSMX – Vanguard Total Stock Market Index Fund Investor Shares, IWM – iShares Russell 2000 ETF, Jpmorgan Chase & Co, Geode Capital Management, Llc, VEXMX – Vanguard Extended Market Index Fund Investor …
